Finance

Beta
Lists
ALXO:NASDAQ
ALX Oncology Holdings Inc
2,10 USD
+1,45%
(+0,030) 1D
2,10 USD
0,00% (0,00)
After hours
Closed: 17-июл., 16:00:01 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ALXO...
Open
2,04 USD
High
2,16 USD
Low
1,98 USD
Mkt. cap
282,58 млн
Avg. vol.
1,74 млн
Volume
765,31 миң
52-wk high
2,66 USD
52-wk low
0,44 USD
EPS
-1,49 USD
Beta
0,42
Shares outstanding
134,56 млн
No. of employees
43
Open
2,04 USD
High
2,16 USD
Low
1,98 USD
Mkt. cap
282,58 млн
Avg. vol.
1,74 млн
Volume
765,31 миң
52-wk high
2,66 USD
52-wk low
0,44 USD
EPS
-1,49 USD
Beta
0,42
Shares outstanding
134,56 млн
No. of employees
43
News stories
From sources across the web
About ALX Oncology Holdings Inc
CEO-
Employees43
Founded2015
HeadquartersЮг Сан Франциско, Калифорния, Америка Кошмо Штаттары
Sector-
Websitealxoncology.com
Analyst ratings
Based on 4 analysts giving stock ratings to ALXO in the past 3 months
Strong buy
Buy
3
Hold
1
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for ALXO in the last 3 months.
Highest
Current 2,10 USD
6,00 USD (+185,71%)
Average
4,67 USD (+122,38%)
Lowest
4,00 USD (+90,48%)
Analyst
Recommendation
Action
Price target
Projected
Date
Sam Slutsky
LifeSci Capital
Hold
Maintained
-
-
05/16/2026
Michael Yee
UBS
Buy
Maintained
6,00 USD
+185,7%
05/12/2026
Allison Bratzel
Piper Sandler
Buy
Maintained
4,00 USD
+90,5%
05/11/2026
Swayampakula Ramakanth
H.C. Wainwright
Buy
Reiterated
4,00 USD
+90,5%
05/11/2026
Derek Archila
Wells Fargo
Buy
Initiated
5,00 USD
+138,1%
03/19/2026
Last report
2026-ж., 8-май
Fiscal period
Q1 2026
EPS / Est. (USD)
-0,17 USD / -0,16 USD
-7,91%miss
Revenue / Est. (USD)
- / 0,00
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
2025-ж. июн.
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
18,02 млн
17,44 млн
17,64 млн
13,61 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5,45 млн
5,09 млн
5,38 млн
5,36 млн
Operating expense
23,47 млн
22,53 млн
23,02 млн
18,97 млн
Total operating expenses
23,47 млн
22,53 млн
23,02 млн
18,97 млн
Operating income
-23,47 млн
-22,53 млн
-23,02 млн
-18,97 млн
Other non operating income
-
-
-
188,00 миң
EBT including unusual items
-25,95 млн
-22,14 млн
-22,85 млн
-17,93 млн
EBT excluding unusual items
-22,77 млн
-22,14 млн
-22,85 млн
-17,93 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-25,95 млн
-22,14 млн
-22,85 млн
-17,93 млн
Net profit margin
-
-
-
-
Earnings per share
-0,44
-
-0,37
-0,15
Interest and investment income
1,11 млн
802,00 миң
573,00 миң
1,18 млн
Interest expense
-405,00 миң
-408,00 миң
-383,00 миң
-331,00 миң
Net interest expenses
701,00 миң
394,00 миң
190,00 миң
851,00 миң
Depreciation and amortization charges
-
-
-
-
EBITDA
-23,28 млн
-22,38 млн
-22,87 млн
-18,82 млн
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer